An interventional study of TMS and sham in Schizophrenia Spectrum Disorder, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston — 8 open to participants now, 8 under way, none of them phase 3. Schizophrenia · The University of Texas Health Science Center, Houston.
Among the 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 with no phase, and was the 9th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →8 of the 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 9–26 · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–60
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–60
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–50
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–60
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 120 across the 11 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
1 of the studies in Schizophrenia by The University of Texas Health Science Center, Houston that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05276050The University of Texas Health Science Center, HoustonCircuitry-Guided Smoking Cessation in Schizophrenia (UH3) | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS) applied to angular gyrus (AG) will improve negative symptoms and/or other psychosis symptoms in schizophrenia spectrum disorders (SSD) patients compared with prefrontal cortex (PFC) or sham.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: TMS
Device: sham
Device: sham
Device: TMS
A wire coil is held on the scalp. Brief electrical currents are passed through the coil and create one or more magnetic pulses that stimulate the brain. For each TMS session, bursts of 3 pulses at 50 Hz are repeated at 5 Hz as a train for 2seconds. The inter-train interval is 8 seconds. There are 20 trains lasting 192 seconds (600pulses) per session. The intensity of TMS stimulations is set to 80-120% of resting motor threshold(RMT).
Participants will receive total of 2 s of theta burst sham stimulation (TBS) trains repeated every 10 s for a total of 20 cycles (600 pulses). No actual magnetic stimulation will occur, still participant hears the TMS sound and a skin sensation
Change in blood-brain barrier (BBB) water exchange rate at AG obtained from MRI scan
Time frame: baseline (before treatment visit 1), midpoint (after treatment visit 10; about 2 weeks from baseline), and end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Negative symptoms as assessed by the Brief Negative Symptom Scale (BNSS)
It includes 13 items across 6 domains: blunted affect, alogia, asociality, anhedonia, avolition, and lack of normal distress. Each item is scored from 0 to 6, with higher scores indicating more severe negative symptoms. The total score ranges from 0 to 78.
Time frame: at baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Positive symptoms as assessed by the Positive and Negative Syndrome Scale (PANSS)
It includes 30 items rated from 1 (absent) to 7 (extreme) across three subscales: Positive Symptoms (7 items; score range 7-49) Negative Symptoms (7 items; score range 7-49) General Psychopathology (16 items; score range 16-112) The PANSS Total Score ranges from 30 to 210, with higher scores indicating more severe symptoms. Change
Time frame: at baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Cognitive function as assessed by Brief Assessment of Cognition in Schizophrenia (BACS): Symbol Coding
Participants are asked to match symbols to numbers according to a key as quickly and accurately as possible within 90 seconds. Scores reflect the total number of correct responses, with higher scores indicating better cognitive performance.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Working memory as assessed by the Number Span test
The Number Span test evaluates working memory capacity by requiring participants to recall sequences of numbers in the same order (forward span) and/or reverse order (backward span). Scores represent the total number of correctly recalled sequences, with higher scores indicating better working memory performance.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Working memory as assessed by the Wechsler Memory Scale-Third Edition (WMS-III): Spatial Span
Participants observe a series of blocks tapped by the examiner and are asked to reproduce the sequence in the same order (Spatial Span Forward) and reverse order (Spatial Span Backward). Scores are based on the number of correctly reproduced sequences, with higher scores indicating better spatial working memory performance.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Cognitive function as assessed by the Category Fluency Test: Animal naming (Fluency)
participants are asked to name as many animals as possible within 60 seconds. The score is the total number of correct, non-repeated animal names, with higher scores indicating better semantic fluency.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Cognitive function as assessed by the Rey-Osterrieth Complex Figure Test
Participants are asked to copy a complex geometric figure and later reproduce it from memory after a delay. Scores are based on the accuracy and placement of figure components, with higher scores indicating better visuospatial and memory performance.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Cognitive function as assessed by the Bell Lysaker Emotion Recognition Task
Participants view brief video clips of an actor expressing various emotions (e.g., happiness, sadness, anger, fear, surprise, disgust, and neutrality) through facial expressions, vocal tone, and body language. Participants identify the emotion portrayed in each clip. Scores reflect the total number of correctly identified emotions, with higher scores indicating better emotion recognition ability.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Cognitive function as assessed by the Hinting Task
Participants read or listen to brief scenarios in which a character implies a desire or intention, and they must identify the underlying meaning. Scores reflect the total number of accurately interpreted hints, with higher scores indicating better theory of mind functioning.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Depression as assessed by the Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a 9-item self-report questionnaire that measures depressive symptom severity over the past two weeks. Each item is scored from 0 (not at all) to 3 (nearly every day), yielding a total score range of 0-27, with higher scores indicating more severe depression.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Depression as assessed by the Calgary Depression Scale
Total score of the Calgary Depression Scale will be reported and ranges from 0 to 27, with a higher score indicating greater depression.
Time frame: t baseline, after treatment visit 10 (about 2 weeks from baseline), and at the end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Resting state functional connectivity between AG and PFC assessed by functional MRI (fMRI)
Time frame: at baseline (before treatment visit 1), midpoint (after treatment visit 10; about 2 weeks from baseline), and end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Activity level (number of steps per day) as assessed by smart wristwatch
Time frame: from baseline (before treatment visit 1) through end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Location (number of unique places visited)as assessed by smart wristwatch
Time frame: from baseline (before treatment visit 1) through end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Sleep (number of hours slept per day) as assessed by smart wristwatch
Time frame: from baseline (before treatment visit 1) through end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Speech (pitch, intonation, pause) as assessed by video recording of speech
Time frame: baseline, after treatment visit 10 (about 2 weeks from baseline), and end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in facial expression (neutral, positive, and negative facial features) as assessed by video recording of speech
Time frame: baseline, after treatment visit 10 (about 2 weeks from baseline), and end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Electrophysiological responses as indicated by mismatch negativity as measured by electroencephalography (EEG)
Mismatch negativity values will be reported in microvolts (uV). Mismatch negativity is measured by subtracting the averaged response to a set of standard stimuli from the average response to deviant stimuli, and taking the amplitude of this difference in a given timepoint.
Time frame: baseline (before treatment visit 1) and end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Change in Electrophysiological response as indicated by steadystate auditory evoked responses from electroencephalography recording (EEG)
Steady-state auditory evoked responses will be reported. The responses are measured by calculating the ratio of the power at target frequency over power at the surrounding background frequencies. The ration will be obtained in a given timepoint.
Time frame: baseline (before treatment visit 1) and end of acute treatment (after treatment visit 20; about 4 weeks from baseline)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Nov 2030, 56 months after the start.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 56 months is above that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →